Fluidigm Corp. (NASDAQ:FLDM) traded down 2.2% during mid-day trading on Thursday . The company traded as low as $8.88 and last traded at $8.91, with a volume of 67,940 shares changing hands. The stock had previously closed at $9.11.

A number of equities research analysts have recently issued reports on the stock. Deutsche Bank AG assumed coverage on shares of Fluidigm Corp. in a report on Wednesday, June 1st. They issued a “buy” rating on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $13.00 target price on shares of Fluidigm Corp. in a report on Thursday, June 2nd. Zacks Investment Research cut shares of Fluidigm Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, May 11th. Finally, Mizuho upped their target price on shares of Fluidigm Corp. from $11.00 to $12.00 and gave the company a “buy” rating in a report on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $13.67.

The stock has a 50-day moving average price of $9.55 and a 200 day moving average price of $8.93. The firm’s market cap is $255.52 million.

Fluidigm Corp. (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.06. During the same period in the prior year, the business posted ($0.53) earnings per share. The business had revenue of $28.20 million for the quarter, compared to analysts’ expectations of $29.62 million. The company’s quarterly revenue was down 1.5% on a year-over-year basis. Equities research analysts expect that Fluidigm Corp. will post ($2.31) earnings per share for the current year.

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.